Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Esperion Theraptc (NQ: ESPR )

25.55 USD -1.20 (-4.49%)
Official Closing Price Updated: 7:58 PM EST, Jan 15, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Esperion Theraptc

< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
NASDAQ: ESPR Long Term Investor Notice: Investigation of Potential Wrongdoing at Esperion Therapeutics, Inc.
San Diego, CA -- (SBWIRE) -- 10/22/2018 -- An investigation was announced for investors in shares of Esperion Therapeutics, Inc. (NASDAQ: ESPR) over possible breaches of fiduciary duties by certain... 
From SBWire - Latest Press Releases
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Esperion (NASDAQ: ESPR), the Lipid Management Company focused on developing and commercializing complementary, convenient, cost-effective, once-daily, oral therapies for the treatment of patients with... 
From GlobeNewswire News Releases
New Research Coverage Highlights Esperion Therapeutics, Summit Therapeutics, Ocwen Financial, Keane Group, Cellectis S.A, and Rapid7 — Consolidated Revenues, Company Growth, and Expectations for 2018
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Esperion Therapeutics, Inc.... 
From GlobeNewswire News Releases
Esperion Announces Positive Top-Line Results from Pivotal Phase 3 Bempedoic Acid / Ezetimibe Combination Pill Study
Esperion (NASDAQ: ESPR) today announced positive top-line results from the pivotal Phase 3 bempedoic acid / ezetimibe combination pill study (1002-053). This trial was a randomized, double-blind,... 
From GlobeNewswire News Releases
Esperion Announces Late-Breaking Oral Presentation of Final Results of Phase 3 Long-Term Safety Study of Bempedoic Acid at the European Society of Cardiology Congress
Esperion (NASDAQ:ESPR) today announced that the final results from the pivotal Phase 3 Study 1 (1002-040 or CLEAR Harmony) were presented at the European Society of Cardiology (ESC) Congress in Munich,... 
From GlobeNewswire News Releases
Market Trends Toward New Normal in Esperion Therapeutics, Oxford Immunotec Global, Limoneira, R1 RCM, Carbonite, and Shenandoah Telecommunications — Emerging Consolidated Expectations, Analyst Ratings
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Esperion Therapeutics, Inc.... 
From GlobeNewswire News Releases
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Esperion (NASDAQ: ESPR), the Lipid Management Company focused on developing and commercializing complementary, convenient, cost-effective, once-daily, oral therapies for the treatment of patients with... 
From GlobeNewswire News Releases
Esperion Provides Bempedoic Acid Franchise Development Program Updates; Reports Second Quarter 2018 Financial Results
Esperion (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing complementary, convenient, cost-effective, once-daily, oral therapies for the treatment of patients with... 
From GlobeNewswire News Releases
Free Technical Research Reports on Biotech Stocks -- Epizyme, Esperion Therapeutics, Exelixis, and Grifols
From PR Newswire
UPCOMING DEADLINES: The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of ESPR, ORA, MFGP, FLR, and REPH
The Klein Law Firm reminds investors that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline... 
From GlobeNewswire News Releases
Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Esperion Therapeutics, Inc. (ESPR) and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. reminds investors that a class action lawsuit has been filed in the U.S. District Court for the Eastern District of Michigan on behalf of all persons or entities who... 
From GlobeNewswire News Releases
DEADLINE TOMORROW: The Schall Law Firm Announces it is Investigating Claims Against Esperion Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
DEADLINE TOMORROW: The Schall Law Firm Announces it is Investigating Claims Against Esperion Therapeutics, Inc. 
From Business Wire News Releases
CLASS ACTION UPDATE for ESPR, SYMC, and PPG: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have... 
From GlobeNewswire News Releases
24 HOUR DEADLINE NOTICE: Kaskela Law LLC Announces Shareholder Class Action Lawsuit Against Esperion Therapeutics, Inc. and Encourages Investors with Losses in Excess of $250,000 to Immediately Contac
A shareholder class action lawsuit has been filed against Esperion Therapeutics, Inc. (NASDAQ: ESPR) (“Esperion” or the “Company”) on behalf of investors who purchased the Company’s common stock... 
From Business Wire News Releases
FRIDAY DEADLINE ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Esperion Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the
FRIDAY DEADLINE ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Esperion Therapeutics, Inc. 
From Business Wire News Releases
Esperion to Host Analyst and Investor Day Event on July 10
Esperion (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing complementary, convenient, cost-effective, once-daily, oral therapies for the treatment of patients with... 
From GlobeNewswire News Releases
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Esperion Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - ESPR
From ACCESSWIRE
DEADLINE REMINDER ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Esperion Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact th
DEADLINE REMINDER ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Esperion Therapeutics, Inc. 
From Business Wire News Releases
SHAREHOLDER ALERT – LC ESPR INWK FLEX KLIC SYMC MFGP FLR REPH: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
The Law Offices of Vincent Wong announce that class actions have commenced on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to... 
From GlobeNewswire News Releases
KESSLER TOPAZ MELTZER & CHECK, LLP: Final Deadline Reminder for Esperion Therapeutics, Inc. Investors - ESPR
From ACCESSWIRE
FINAL DEADLINE NOTICE: Kaskela Law LLC Announces Shareholder Class Action Lawsuit Against Esperion Therapeutics, Inc. and Encourages Investors with Losses in Excess of $250,000 to Immediately Contact
A shareholder class action lawsuit has been filed against Esperion Therapeutics, Inc. (NASDAQ:ESPR) (“Esperion” or the “Company”) on behalf of investors who purchased the Company’s common stock between... 
From GlobeNewswire News Releases
FINAL DEADLINE ALERT: Kaskela Law LLC Announces Shareholder Class Action Lawsuit Against Esperion Therapeutics, Inc. and Encourages Investors with Losses in Excess of $250,000 to Immediately Contact t
From ACCESSWIRE
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Esperion Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - ESPR
From ACCESSWIRE
CLASS ACTION UPDATE for ESPR, PPG and PCG: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have... 
From GlobeNewswire News Releases
KESSLER TOPAZ MELTZER & CHECK, LLP: Important Deadline Reminder for Esperion Therapeutics, Inc. Investors
From ACCESSWIRE
UPCOMING DEADLINES: The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of LC, ESPR, and MFGP
The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to... 
From GlobeNewswire News Releases
SHAREHOLDER ALERT – MOH ESPR PPG ANW QCOM UNM COOL: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
The Law Offices of Vincent Wong announce that class actions have commenced on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to... 
From GlobeNewswire News Releases
UPCOMING DEADLINES: The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of INWK, ESPR, PRTA, and PPG
The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to... 
From GlobeNewswire News Releases
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Esperion Therapeutics, Inc. of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of July 6, 2018 – ESPR
The following statement is being issued by Levi & Korsinsky, LLP: 
From GlobeNewswire News Releases
ESPR ALERT: Pawar Law Group Announces a Securities Class Action Lawsuit Against Esperion Therapeutics, Inc. - ESPR
From ACCESSWIRE
< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.